|Day Low/High||148.25 / 158.59|
|52 Wk Low/High||118.11 / 176.90|
Would love to know if Warren Buffett is adding here, or keeping his powder dry. Would simply love to know.
Imagine not taking action to make commerce as liquid as possible ahead of a pending national crisis, because one was afraid to be perceived as panicked? The Fed was far from cowardly on Tuesday.
I would still like to see a day where the broad indices perform well on volume that grows from the day prior, but is that because I am too experienced?
VEEV provides cloud-based software for the life sciences industry.
There are times when the indices fail to tell the story of what is really going on.
The CAD/CAM software giant is down sharply after blaming European and Chinese macro uncertainty for a slight cut in its full-year guidance.
VEEV likely to correct for several more weeks, but an opportunity to buy may be awaiting.
AbbVie is dropping on Allergan deal announcement, momentum is weak outside certain pockets.
This cloud earnings season has been about the bigger established names.
These trade tariffs will have a big effect beyond just autos.
Longs should protect their profits and positions in this name.
Traders should focus on the first-day post-earnings move.
Examining the influential short-sellers' big winners and losers provides important insights into trading and investing.
Prices could surprise traders and investors on the upside in the weeks ahead.
Recent earnings reports from several major software firms suggest business trends remain pretty good for the group.
The momentum of acquisitions isn't stalling. Here's what names might be in the mix.
I can see this group bottoming a heck of a lot faster than others.
VEEV's price chart that is showing weakness.
I did want to hit up cannabis/Canada today, but I will be back same time, same channel next week, so I'm going to call an audible and push that until next week so I can finish up with my spec list today. 1) POTENTIAL BUYER: Intuit Potential Target: ...
We see a notable shift away from traditional large-cap pharmaceutical stocks to more specialized niches.
This trade is based on fundamentals and the current volatility priced into the options market.
Though much bigger than they were a few years ago, top cloud-only software vendors are still posting very strong sales growth.
I'd love nothing more than to see this one sell off to $59 on a strong report.